ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,199.50
      -0.77%
      US Tech 100
      17,301.60
      -1.59%
      Dow Jones
      38,763.45
      -0.60%
      Brent Oil
      78.42
      3.16%
      Bitcoin
      55,411.93
      -1.16%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. FibroGen Inc (FGEN)

      7. FibroGen Inc (FGEN) News

      FGEN

      FibroGen (FGEN)

      FibroGen Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:FGEN
      DateTimeSourceHeadlineSymbolCompany
      08/07/20245:10PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FGENFibroGen Inc
      08/07/20245:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
      08/06/20244:11PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
      08/06/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
      08/06/20244:05PMGlobeNewswire Inc.FibroGen Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:FGENFibroGen Inc
      08/05/20244:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      07/30/20244:07PMGlobeNewswire Inc.FibroGen to Report Second Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
      07/30/20244:05PMGlobeNewswire Inc.FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate UpdateNASDAQ:FGENFibroGen Inc
      07/11/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FGENFibroGen Inc
      07/08/20244:32PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:FGENFibroGen Inc
      06/18/20248:00AMGlobeNewswire Inc.FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024NASDAQ:FGENFibroGen Inc
      06/13/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/10/20246:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/07/20247:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/07/20247:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/07/20244:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
      06/06/20248:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/06/20248:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/06/20248:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/06/20248:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/06/20248:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/06/20248:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/06/20248:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
      06/03/20244:05PMGlobeNewswire Inc.FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical TrialsNASDAQ:FGENFibroGen Inc
      06/03/20244:02PMGlobeNewswire Inc.FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid TumorsNASDAQ:FGENFibroGen Inc
      06/03/20247:00AMGlobeNewswire Inc.FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:FGENFibroGen Inc
      05/23/20245:05PMGlobeNewswire Inc.FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical OncologyNASDAQ:FGENFibroGen Inc
      05/07/202411:55AMAllPennyStocks.comTraders Rush To Buy Biotech Following Q1 Earnings BeatNASDAQ:FGENFibroGen Inc
      05/07/20247:00AMGlobeNewswire Inc.FibroGen to Participate in Upcoming Investor ConferencesNASDAQ:FGENFibroGen Inc
      05/06/20244:10PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
       Showing the most relevant articles for your search:NASDAQ:FGEN

      Your Recent History

      BIT
      P217R9
      NLBNPIT217R9 20991231 99...
      Delayed Upgrade Clock